Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Fatty liver screening
Introduction
Please help WikiDoc by adding content here. It’s easy! Click here to learn about editing.
Overview
Overview
Screening
Screening
Per the American Gastroenterological Association (AGA) in 2021[1], screening should be:
- Diabetes mellitus Type 2
- 2 or more metabolic risk factors (entral obesity, high triglycerides, low HDL cholesterol, hypertension, prediabetes, or insulin resistance)
- Excessive alcohol intake
- Steatosis on any imaging modality or elevated aminotransferases
Per the American Association for the Study of Liver Diseases (AASLD) in 2023[2]:
- “All patients with hepatic steatosis or clinically suspected NAFLD based on the presence of obesity and metabolic risk factors should undergo primary risk assessment with FIB-4.”
References
References
- ↑ Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E; et al. (2021). “Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease”. Gastroenterology. 161 (5): 1657–1669. doi:10.1053/j.gastro.2021.07.049. PMC 8819923 Check
|pmc=value (help). PMID 34602251 Check|pmid=value (help). - ↑ Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D; et al. (2023). “AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease”. Hepatology. doi:10.1097/HEP.0000000000000323. PMID 36727674 Check
|pmid=value (help).
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: